Pancreatic Cancer Research

ResearcherHiroshima UniversityNo recent work listed

Hiroyuki Otsuka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5193-4378; OpenAlex author ID A5005584964. Sources: OpenAlex.

Their work

Papers
17
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2020: 3 papers · 2021: 5 papers · 2022: 6 papers · 2023: 3 papers

Papers 17

  1. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-023-03009-w↗
  2. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-023-03073-2↗
  3. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutatio… Co-author DOI 10.1007/s12328-022-01741-2↗
  4. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using invers… Co-author DOI 10.1002/jhbp.1151↗
  5. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. Co-author DOI 10.1007/s00423-021-02339-x↗
  6. Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pan… Co-author DOI 10.1007/s12328-022-01621-9↗
  7. Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.12.009↗
  8. Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative … Co-author DOI 10.1016/j.pan.2022.03.018↗
  9. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2022.04.004↗
  10. Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. Co-author DOI 10.1007/s00423-020-02025-4↗
  11. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. Co-author DOI 10.1007/s11605-021-04978-3↗
  12. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial… Co-author DOI 10.1016/j.ejca.2021.10.012↗
  13. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.022↗
  14. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. Co-author DOI 10.1159/000520064↗
  15. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. Co-author DOI 10.1002/jhbp.737↗
  16. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. Co-author DOI 10.1007/s00423-020-01914-y↗
  17. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.08.019↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenjiro Okada · 17 shared papers, 2020–2023 · strength 2.44
  2. Shin’ya Takahashi · 17 shared papers, 2020–2023 · strength 2.44
  3. Kenichiro Uemura · 17 shared papers, 2020–2023 · strength 2.44
  4. Tatsuaki Sumiyoshi · 15 shared papers, 2020–2023 · strength 2.20
  5. Yoshiaki Murakami · 15 shared papers, 2020–2023 · strength 2.11
  6. Naru Kondo · 14 shared papers, 2020–2022 · strength 1.93
  7. Yasutaka Ishii · 5 shared papers, 2021–2023 · strength 0.79
  8. Tomofumi Tsuboi · 3 shared papers, 2021–2023 · strength 0.43
  9. Ryuta Shintakuya · 2 shared papers, 2023 · strength 0.34
  10. Yoshiyuki Shibata · 2 shared papers, 2022–2023 · strength 0.33
  11. Takuya Sakoda · 2 shared papers, 2021–2022 · strength 0.29
  12. Kenta Baba · 1 shared paper, 2023 · strength 0.16
  13. Takeshi Sudo · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.